Catalent Inc (CTLT) Announces Quarterly Earnings Results
Catalent Inc (NASDAQ:CTLT) issued its quarterly earnings data on Monday. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.08, Bloomberg Earnings reports. The firm had revenue of $616.90 million during the quarter, compared to the consensus estimate of $547.48 million. Catalent had a net margin of 4.88% and a return on equity of 16.95%. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period last year, the business posted $0.52 earnings per share.
Shares of Catalent (CTLT) opened at 40.27 on Wednesday. The company has a market cap of $5.03 billion and a PE ratio of 47.43. The firm’s 50 day moving average is $35.14 and its 200-day moving average is $32.37. Catalent has a 1-year low of $21.83 and a 1-year high of $41.37.
ILLEGAL ACTIVITY NOTICE: “Catalent Inc (CTLT) Announces Quarterly Earnings Results” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/catalent-inc-ctlt-announces-quarterly-earnings-results/1531566.html.
In related news, SVP Christine Dolan sold 745 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $34.85, for a total transaction of $25,963.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
A number of large investors have recently added to or reduced their stakes in the stock. Flinton Capital Management LLC increased its stake in Catalent by 17.7% in the first quarter. Flinton Capital Management LLC now owns 3,616 shares of the company’s stock worth $102,000 after buying an additional 544 shares during the last quarter. Acrospire Investment Management LLC increased its stake in Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares during the last quarter. Quantbot Technologies LP increased its stake in Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after buying an additional 1,804 shares during the last quarter. Meadow Creek Investment Management LLC increased its stake in Catalent by 17.7% in the first quarter. Meadow Creek Investment Management LLC now owns 4,972 shares of the company’s stock worth $141,000 after buying an additional 748 shares during the last quarter. Finally, Acadian Asset Management LLC increased its stake in Catalent by 115.7% in the first quarter. Acadian Asset Management LLC now owns 5,847 shares of the company’s stock worth $166,000 after buying an additional 3,136 shares during the last quarter.
Several equities research analysts have issued reports on the stock. J P Morgan Chase & Co restated a “buy” rating and set a $40.00 price objective on shares of Catalent in a research report on Tuesday. BidaskClub upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Jefferies Group LLC reiterated a “hold” rating and issued a $38.00 price target (up from $35.00) on shares of Catalent in a research report on Tuesday. William Blair reiterated an “ourperform” rating on shares of Catalent in a research report on Tuesday. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $45.00 price target on shares of Catalent in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Catalent presently has an average rating of “Buy” and an average price target of $35.88.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.